AtaGenix Laboratories
AtaGenix Laboratories
Release time: 2026-04-29 View volume: 8
The AACR Annual Meeting 2026 brought together more than 22,000 researchers, clinicians, and advocates in San Diego for six days of science that reaffirmed why cancer research continues to accelerate. Under this year's theme — Precision, Partnership, Purpose: Advancing Cancer Science to Save Lives Globally — the meeting delivered landmark presentations on AI-driven drug discovery, circulating tumor DNA (ctDNA)-guided treatment decisions, next-generation immune checkpoint combinations, and the expanding pipeline of antibody–drug conjugates (ADCs).
AtaGenix was on the ground at Booth #1761, meeting researchers, discussing reagent sourcing challenges, and sharing how our custom antibody development services and the abinScience catalog can support the science moving forward.
The conversations at our booth — and the science presented across plenary sessions and poster halls — converged on several themes that directly connect to what we do every day:
From ctDNA-based minimal residual disease (MRD) monitoring to tumor-informed assay development, precision oncology demands validated, reproducible reagents at every workflow step — from target discovery through companion diagnostic development.
AstraZeneca presented a dual-payload anti-CD30 ADC (dpADC) using non-natural amino acid conjugation, J&J's JNJ-89862175 targets the emerging antigen ENPP3, and CStone's CS5007 explores EGFR×HER3 bispecific ADC for tumor heterogeneity. This rapid pipeline expansion is driving accelerating demand for anti-idiotype antibodies, PK/ADA assay kits, and custom antibody pairs for immunogenicity testing.
Beyond PD-1/PD-L1, targets like B7-H3, TIGIT, and LAG-3 drew significant attention. Palleon's E-688/HLX316 — a B7-H3-targeted sialidase fusion protein — generated buzz with a novel glycobiology mechanism, while AstraZeneca's AZD8359 targets STEAP2 to open new territory in prostate cancer T-cell therapy. Researchers pursuing these directions need high-purity, low-endotoxin in vivo-grade antibodies and recombinant proteins.
NCI Director Anthony Letai highlighted cancer vaccines as a key research priority. Vaccine candidate screening relies heavily on recombinant antigen proteins, cytokine panels, and functional antibodies — core categories in the abinScience catalog.
The most talked-about targets at this year's meeting are well-covered in the abinScience catalog. Here's a snapshot of the key research directions and our in-stock reagent coverage:
| Target | Research Direction | Product Types | SKUs |
|---|---|---|---|
| EGFR | Targeted degradation, bispecific ADCs, resistance mutation studies | Antibodies · Proteins · Biosimilars | 186 → |
| ALK | Molecular glue degradation, ALK fusion protein targeting, resistance mechanisms | Antibodies · Proteins · Biosimilars | 137 → |
| PD-L1 | Immune checkpoint blockade, ADC payload delivery, combination therapies | Antibodies · Proteins · Biosimilars | 132 → |
| TIGIT | Emerging checkpoint, PD-1/PD-L1 combination strategies | Antibodies · Proteins · Biosimilars | 55 → |
| LAG-3 | Emerging checkpoint, expanding indications in combination immunotherapy | Antibodies · Proteins · Biosimilars | 55 → |
| B7-H3 | Tumor glycobiology, sialidase fusion proteins, emerging ADC target | Antibodies · Proteins · Biosimilars | 39 → |
| CD30 | Dual-payload ADC development, lymphoma-targeted therapy | Antibodies · Proteins · Biosimilars | 39 → |
| HER3 | Bispecific ADC strategies, tumor heterogeneity | Antibodies · Proteins · Biosimilars | 39 → |
| ENPP3 | Emerging ADC target, renal and lung cancer applications | Antibodies · Proteins · Biosimilars | 12 → |
| STEAP2 | T-cell engager target, prostate cancer immunotherapy | Antibodies · Proteins | 7 → |
All products are searchable and available for order at abinscience.com. For specific clones, conjugates, or bulk pricing, contact our technical team.
Whether your project starts with target validation or extends through drug development, we provide the tools and services to keep it moving:
AtaGenix — Custom CRO Services
abinScience — Catalog Reagents
We had meaningful conversations throughout the week — about reagent reproducibility, timeline pressures in drug development programs, and how to source quality tools without the markup. These conversations are exactly why we attend AACR every year, and they shape the products and services we build.
The booth is closed, but the work continues. If we connected at AACR and you'd like to follow up on a quote, technical question, or project discussion, our team is ready.
Continue the conversation
Custom projects, catalog sourcing, or technical support — we're here to help.
info@atagenix.com | info@abinscience.com
AtaGenix Laboratories is a Wuhan-based antibody and protein CRO with 15 years of experience in custom antibody development, recombinant protein expression, and stable cell line construction. Our catalog brand, abinScience, offers over 35,000 research reagents — including antibodies, recombinant proteins, ELISA kits, research biosimilars, and in vivo-grade antibodies — to researchers worldwide. For Research Use Only.
Contact Us
+86-27-6552-3339
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
